Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aveo Pharmaceuticals (AVEO)

Aveo Pharmaceuticals (AVEO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 113,566
  • Shares Outstanding, K 160,744
  • Annual Sales, $ 5,410 K
  • Annual Income, $ -5,330 K
  • 60-Month Beta 0.75
  • Price/Sales 16.65
  • Price/Cash Flow N/A
  • Price/Book 50.59
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.16
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/08/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.03
  • Number of Estimates 3
  • High Estimate 0.01
  • Low Estimate -0.05
  • Prior Year -0.03
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.47 +50.58%
on 11/06/19
0.96 -26.48%
on 10/17/19
-0.12 (-14.78%)
since 10/11/19
3-Month
0.47 +50.58%
on 11/06/19
1.12 -36.92%
on 09/17/19
+0.05 (+7.06%)
since 08/13/19
52-Week
0.47 +50.58%
on 11/06/19
2.25 -68.60%
on 11/26/18
-1.15 (-62.02%)
since 11/13/18

Most Recent Stories

More News
AVEO Pharmaceuticals (AVEO) Q3 Earnings & Revenues Top Mark

AVEO Pharmaceuticals (AVEO) rides high on both earnings and revenue beat in the third quarter. Shares rise.

BMY : 58.79 (+0.69%)
AZN : 47.82 (+1.57%)
BAYRY : 19.3800 (unch)
AVEO : 0.71 (+26.09%)
AVEO: 3Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ AVEO Pharmaceuticals Inc. (AVEO) on Tuesday reported third-quarter net income of $16.4 million, after reporting a loss in the same period a year earlier.

AVEO : 0.71 (+26.09%)
AVEO Reports Third Quarter 2019 Financial Results and Provides Business Update

AVEO Oncology (NASDAQ: AVEO) today reported financial results for the third quarter ended September 30, 2019 and provided a business update.

AVEO : 0.71 (+26.09%)
Spectrum Pharma's (SPPI) Q3 Loss Narrows, Focus on Rolontis

Spectrum Pharma (SPPI) posts a narrower-than-expected loss for the third quarter of 2019.

ALKS : 19.39 (-2.54%)
AVEO : 0.71 (+26.09%)
ANIK : 60.53 (+0.13%)
SPPI : 8.25 (+1.85%)
Global Blood's (GBT) Q3 Loss Widens, Voxelotor in Focus

Global Blood (GBT) incurs a wider-than-expected loss in the third quarter of 2019. Moreover, voxelotor for the treatment of sickle cell disease is under review in the United States.

RHHBY : 37.6000 (+0.29%)
GBT : 50.24 (+3.84%)
ALKS : 19.39 (-2.54%)
AVEO : 0.71 (+26.09%)
Zoetis (ZTS) Beats on Earnings in Q3, Reports In-Line Sales

Zoetis (ZTS) beats earnings estimates, while sales are in line in the third quarter of 2019.

ACOR : 1.93 (-2.53%)
AVEO : 0.71 (+26.09%)
ALKS : 19.39 (-2.54%)
ZTS : 116.45 (-0.64%)
Horizon Therapeutics' (HZNP) Q3 Earnings Beat Estimates

Horizon Therapeutics (HZNP) beats earnings and sales estimates in the third quarter of 2019.

ACOR : 1.93 (-2.53%)
HZNP : 30.30 (+0.23%)
AVEO : 0.71 (+26.09%)
ALKS : 19.39 (-2.54%)
AVEO Oncology and Biodesix Announce Initiation of the CyFi-2 Study, a Phase 2 Randomized Study of Ficlatuzumab in Combination with High-Dose Cytarabine vs. High-Dose Cytarabine Alone in Patients with Relapsed and Refractory AML

AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the initiation of the CyFi-2 study, a randomized Phase 2 clinical study evaluating ficlatuzumab, AVEO's potent hepatocyte growth factor (HGF)...

AVEO : 0.71 (+26.09%)
Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q3

Ultragenyx (RARE) reports wider-than-expected loss and misses sales estimates in the third quarter of 2019.

BAYRY : 19.3800 (unch)
AVEO : 0.71 (+26.09%)
RARE : 37.28 (+0.54%)
ASLN : 0.37 (-24.78%)
Intercept (ICPT) Earnings and Sales Miss Estimates in Q3

Intercept (ICPT) reports a wider-than-expected loss and misses on sales in the third quarter of 2019.

ACOR : 1.93 (-2.53%)
ICPT : 83.92 (+1.08%)
AVEO : 0.71 (+26.09%)
ASLN : 0.37 (-24.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade AVEO with:

Business Summary

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing and commercializing novel cancer therapeutics. Its product candidates are targeted against important mechanisms known or believed to be involved in cancer. Tivozanib, the Company's lead product candidate, is...

See More

Key Turning Points

2nd Resistance Point 0.84
1st Resistance Point 0.77
Last Price 0.71
1st Support Level 0.60
2nd Support Level 0.50

See More

52-Week High 2.25
Fibonacci 61.8% 1.57
Fibonacci 50% 1.36
Fibonacci 38.2% 1.15
Last Price 0.71
52-Week Low 0.47

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar